EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): UPDATED SAFETY ANALYSIS

被引：0
|
作者：
Nicolini, F. [1 ]
Alimena, G. [2 ]
Shen, Z. [3 ]
Al-Ali, H. -K [4 ]
Turkina, A. [5 ]
Smith, G. [6 ]
Pasquini, R. [7 ]
Jootar, S. [8 ]
Hsu, Y. [9 ]
Veronese, M. L. [9 ]
Powell, B. [10 ]
机构：
[1] Hop Edouard Herriot, Lyon, France
[2] Univ Roma La Sapienza, Rome, Italy
[3] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China
[4] Univ Leipzig, Med Klin & Poliklin 2, Leipzig, Germany
[5] Hematol Sci Ctr, Moscow, Russia
[6] Leeds Teaching Hosp, Leeds, W Yorkshire, England
[7] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil
[8] Mahidol Univ, Salaya, Thailand
[9] Nova Pharmaceut Corp, E Hanover, NJ USA
[10] Wake Forest Univ, Baptist Med Ctr, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O134
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [21] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure
    Onaka, Takashi
    Takahashi, Naoto
    Miura, Masatomo
    Yonezawa, Akihito
    Imada, Kazunori
    Sawada, Kenichi
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (04) : 451 - 451
  • [23] Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party
    Lee, Jeong-Ok
    Kim, Inho
    Chung, Joo-Seop
    Kim, Yeo-Kyeoung
    Yhim, Ho-Young
    Kim, Dae-Young
    Do, Young-Rok
    Seong, Chu-Myong
    Nam, Seung-Hyun
    Kim, Sung-Hyun
    Lee, Jae-Hoon
    Park, Jinny
    Kim, Jin Seok
    Min, Yoo-Hong
    Sohn, Sang Kyun
    Joo, Young Don
    Bae, Sung-Hwa
    Oh, Sukjoong
    Zang, Dae Young
    Lee, Hong Ghi
    Yoon, Sung-Soo
    Park, Seonyang
    BLOOD, 2012, 120 (21)
  • [24] Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
    Francis J. Giles
    Ophelia Q. P. Yin
    William M. Sallas
    Philipp D. le Coutre
    Richard C. Woodman
    Oliver G. Ottmann
    Michele Baccarani
    Hagop M. Kantarjian
    European Journal of Clinical Pharmacology, 2013, 69 : 813 - 823
  • [25] Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
    Giles, Francis J.
    Yin, Ophelia Q. P.
    Sallas, William M.
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (04) : 813 - 823
  • [26] Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
    Takahashi N.
    Miura M.
    Kuroki J.
    Mitani K.
    Kitabayashi A.
    Sasaki O.
    Kimura H.
    Imai K.
    Tsukamoto N.
    Noji H.
    Kondo T.
    Motegi M.
    Kato Y.
    Mita M.
    Saito H.
    Yoshida C.
    Torimoto Y.
    Kimura T.
    Wano Y.
    Nomura J.
    Yamamoto S.
    Mayama K.
    Honma R.
    Sugawara T.
    Sato S.
    Shinagawa A.
    Abumiya M.
    Niioka T.
    Harigae H.
    Sawada K.
    Biomarker Research, 2 (1)
  • [27] Safety, and efficacy of nilotinib dose escalation 600mg BID in patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP)
    Hochhaus, Andreas
    Giles, Francis J.
    le Coutre, Philipp
    Baccarani, Michele
    Gattertnann, Norbert
    Bhalla, Kapil N.
    Alimena, Giuliana
    Ossenkoppele, Gert
    Nicolini, Franck
    Litzow, Mark R.
    Bbatia, Ravi
    Cervantes, Francisco
    Wang, Jim
    Woodman, Richard
    Cortes, Jorge
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 314A - 315A
  • [28] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [29] THE BUDGET IMPACT ANALYSIS OF NILOTINIB IN THE SECOND-LINE TREATMENT OF IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA
    Huang, C.
    Shen, L.
    Liu, Y.
    VALUE IN HEALTH, 2018, 21 : S96 - S96
  • [30] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    Cortes, J.
    Kim, D-W
    Raffoux, E.
    Martinelli, G.
    Ritchie, E.
    Roy, L.
    Coutre, S.
    Corm, S.
    Hamerschlak, N.
    Tang, J-L
    Hochhaus, A.
    Khoury, H. J.
    Bruemmendorf, T. H.
    Michallet, M.
    Rege-Cambrin, G.
    Gambacorti-Passerini, C.
    Radich, J. P.
    Ernst, T.
    Zhu, C.
    Van Tornout, J. M. A.
    Talpaz, M.
    LEUKEMIA, 2008, 22 (12) : 2176 - 2183
12345